Blogs

When will companies stop babysitting the NANNIs for their clinical trials? 5 key takeaways from SCOPE 2020

SCOPE continues to be a central location for industry colleagues to meet and exchange ideas around clinical development. We had a great time at the 2020 meeting catching up with friends, clients and colleagues, as well as co-moderating a roundtable on protocol design and chairing a main session on site selection with esteemed industry practitioners. It was a whirlwind of…

Less artificial…More INTELLIGENCE

In the industry of clinical research, we are accustomed to working with conservative companies that make decisions slowly.  Look at the adoption of EDC – over how many decades now?  Understandable, at least to a point.   I’ve been in my new role at  Phesi for 2 weeks now, and I am witnessing a refreshing change.  Artificial intelligence started to sneak…

Delivering NASH trials in a competitive world using ClinSite

In our last blog we talked about the importance of site level insights in making solid decisions about which investigators can successfully support your trial. In this blog we give further insights about how ClinSite can support decision making on investigator site selection in NASH, a fiercely competitive space for investigator site patient enrollment. When we launched ClinSite at DIA…

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.